Trial Profile
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2016
Price :
$35
*
At a glance
- Drugs FG 2216 (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors FibroGen
- 18 Feb 2016 New trial record